PE-backed BayMark Health Services makes two acquisitions

BayMark Health Services, which is backed by Webster Capital, has acquired Louisiana-based AppleGate Recovery, an addiction recovery clinic and Virginia-based Coleman Institute, a detox program for opiates provider. No financial terms were disclosed. BayMark is  provider of opioid treatment services.


Lewisville, Texas (February 6, 2017) – BayMark Health Services, a portfolio company of Webster Capital and national provider of opioid treatment services, has completed its second acquisition in 2017 and seventh in the last 18 months.

In 2017, BayMark has extended its service lines into office based buprenorphine with its purchase of Louisiana based AppleGate and ambulatory detox services with its purchase of Virginia based Coleman Institute. BayMark CEO, Dave White, remarked, “It is exciting to see expansion into new service lines and geographies as we believe there are significant growth opportunities in the years to come.” Webster Co-Managing Partner, David Malm, said, “With the state of opioid abuse in the country, BayMark is focused on providing care through multiple approaches in as many areas as possible to address the epidemic.”

Webster initially invested in BayMark in 2015 with the goal of providing care to those impacted by opioid abuse.

About BayMark Health Services
BayMark Health Services, headquartered in Lewisville, Texas, is a specialty health care organization whose core business is to provide evidence-based treatment services for opioid addiction and dependency with 65 treatment locations in 15 states, treating over 25,000 patients daily in their recovery from opioid addiction. BayMark’s outpatient programs provide medically supervised treatment for addiction to prescription pain medications and other opioids; offering a selection of medication treatment options and counseling services in a wide variety of settings focused on meeting the individual needs of our patients. Our continuum of programs currently include treatment with methadone and buprenorphine in highly structured Opioid Treatment Programs (OTPs), treatment with buprenorphine in less structured office based settings (OBOT), and medically supervised detoxification combined with Vivitrol or longer term injectable implants. For further information, please visit

About Webster Capital
Founded in 2003, Webster Capital is a private equity firm, which helps companies unlock their potential. Webster focuses on branded consumer and healthcare services companies with EBITDA between $3 million to $20 million. Webster Capital provides equity financing, expertise, and a broad contact network for management buyouts and growth capital. At present, Webster has raised over $600 million and is currently investing Fund III, a $400 million fund raised in 2014. For additional information on Webster Capital, please visit